#Business #WallStreet
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
WSJ.com: US Business
PAID
This is a business article located in the U.S. Business section of the Wall Street Journal. For the latest articles on U.S. business, current markets and other business related news follow our Twitter Page or bookmark this website.
